CBG Explained: The Cannabinoid That Comes From Cannabis's Original Building Block

November 15, 2026 at 6:46 am|By nuggnotes Media
A young green cannabis seedling beside a small empty glass vial on a dark slate surface in window light

The Real "Mother Cannabinoid"

CBGA, or cannabigerolic acid, is the plant's original cannabinoid building block. Three enzymes convert CBGA into THCA, CBDA and CBCA. CBG forms only when leftover CBGA loses its acid group through heat, light or time. CBG does not convert into another cannabinoid inside the plant.

Diagram: the plant builds CBGA first; three synthase enzymes convert it into THCA, CBDA and CBCA, which become THC, CBD and CBC with heat. CBG is the un-converted remainder of CBGA after heat and time. The mother cannabinoid is CBGA — CBG is the leftover, not the parent

Why CBG Is Rare

As cannabis flowers mature, those enzymes use up most of the available CBGA. As a result, typical mature drug-type flower contains roughly 1% CBG or less. CBG-rich chemotype IV plants are different: their THCA and CBDA synthase genes do not function normally, so CBGA accumulates instead of converting into other cannabinoids.

How CBG Interacts With the Body

CBG is non-intoxicating. It binds weakly to the CB1 and CB2 receptors and acts as a partial agonist at CB2 in laboratory assays. Its strongest documented receptor actions occur in laboratory models: it is a potent alpha-2 adrenoceptor agonist in mouse brain tissue, and it acts as a 5-HT1A receptor antagonist in laboratory assays. Those findings have not been demonstrated as human effects.

What the Human Trials Found

Controlled human research is still thin — three small studies. In a 2024 double-blind, placebo-controlled crossover field trial, 34 healthy adults took a single 20 mg dose of CBG: it significantly reduced self-rated anxiety and stress, and it also enhanced verbal memory relative to placebo, with no intoxication or impairment.

A randomized, triple-blind trial in veterans with sleep problems — 63 people randomized, 35 of whom completed without major protocol deviations — tested 25 mg of CBG daily, then 50 mg daily, over four weeks. Sleep scores improved in both groups, with no statistically significant difference between CBG and placebo. CBG was well tolerated.

And in a 2026 laboratory study, 12 healthy adults took single doses of CBG up to 200 mg. No drug-related adverse events occurred and the effects were minimal, though blood levels varied widely from person to person.

What a Survey Can and Cannot Show

A 2022 survey of 127 people who had already chosen to use CBG products reported perceived benefits. Because it surveyed existing users and relied on self-reports, it does not establish that CBG is effective.

CBG's Antibacterial Findings

In a 2020 McMaster University study, CBG killed MRSA bacteria, prevented biofilm formation, eradicated antibiotic-persistent cells and worked in infected mice. The compound was also toxic to host cells. The researchers described it as an important lead rather than a likely final product. No human antibacterial data exist.

Animal-Only Findings

Other results come only from animals. CBG stimulated appetite in rats, reduced colitis inflammation in mice, showed neuroprotection in Huntington's-model mice and lowered eye pressure in cats in a 1984 study. None of these effects has been shown in humans.

Approval and Safety

No CBG medicine is approved by the FDA or the European Medicines Agency. The FDA includes CBG among emerging cannabinoids marketed with unapproved therapeutic claims. Human safety data are still thin — the controlled studies are small and short — and long-term safety, pregnancy risks and clinically important drug interactions remain inadequately characterized.

Myths to Correct

"Stem cell cannabinoid" is a marketing phrase with no biological basis. CBG is not the mother cannabinoid; CBGA is. CBG also does not convert into THC or CBD inside the human body.

Sources

  1. Fellermeier M, Zenk MH. "Prenylation of olivetolate by a hemp transferase yields cannabigerolic acid, the precursor of tetrahydrocannabinol." FEBS Letters, 1998. DOI: 10.1016/S0014-5793(98)00450-5.
  2. Gagne SJ et al. "Identification of Olivetolic Acid Cyclase..." Proceedings of the National Academy of Sciences, 2012. PMID: 22802619.
  3. Luo X et al. "Complete Biosynthesis of Cannabinoids and Their Unnatural Analogues in Yeast." Nature, 2019. PMID: 30814733.
  4. de Meijer EPM et al. "The Inheritance of Chemical Phenotype in Cannabis sativa L." Genetics, 2003.
  5. Navarro G et al. "Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes." Frontiers in Pharmacology, 2018. PMID: 29977202.
  6. Cascio MG et al. "Evidence That the Plant Cannabinoid Cannabigerol Is a Highly Potent α2-Adrenoceptor Agonist and Moderately Potent 5-HT1A Receptor Antagonist." British Journal of Pharmacology, 2010. PMID: 20002104.
  7. Cuttler C et al. "Acute Effects of Cannabigerol on Anxiety, Stress, and Mood: A Double-Blind, Placebo-Controlled, Crossover, Field Trial." Scientific Reports, 2024. PMID: 39003387.
  8. Russo EB et al. "Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms." Cannabis and Cannabinoid Research, 2022. PMID: 34569849.
  9. Farha MA et al. "Uncovering the Hidden Antibiotic Potential of Cannabis." ACS Infectious Diseases, 2020. PMID: 32017534.
  10. Appendino G et al. "Antibacterial Cannabinoids from Cannabis sativa: A Structure-Activity Study." Journal of Natural Products, 2008. PMID: 18681481.
  11. U.S. Food and Drug Administration. Cannabis Derived Products Data Acceleration Plan.
  12. Effect of Cannabigerol on Sleep and Quality of Life in Veterans: A Decentralized, Randomized, Placebo-Controlled Trial. Medical Cannabis and Cannabinoids, 2025. PMID: 41574318. DOI: 10.1159/000549902. ClinicalTrials.gov: NCT05088018.
  13. Safety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults. Journal of Pharmacology and Experimental Therapeutics, 2026.

0 comments

Leave a comment